Shi Ming Tu
About
In The Last Decade
Shi Ming Tu
10 papers receiving 349 citations
Peers
Comparison fields: 5 of 53
- Pulmonary and Respiratory Medicine 246
- Cancer Research 104
- Oncology 103
- Molecular Biology 80
- Surgery 79
Countries citing papers authored by Shi Ming Tu
This map shows the geographic impact of Shi Ming Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi Ming Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi Ming Tu more than expected).
Fields of papers citing papers by Shi Ming Tu
This network shows the impact of papers produced by Shi Ming Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi Ming Tu. The network helps show where Shi Ming Tu may publish in the future.
Co-authorship network of co-authors of Shi Ming Tu
This figure shows the co-authorship network connecting the top 25 collaborators of Shi Ming Tu. A scholar is included among the top collaborators of Shi Ming Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shi Ming Tu. Shi Ming Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis. | 2 |
| 2 | 4 | |
| 3 | 185 | |
| 4 | Variant prostate carcinoma and elevated serum CA-125. | 7 |
| 5 | 8 | |
| 6 | 31 | |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 7 | |
| 10 | 15 | |
| 11 | 46 | |
| 12 | Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. | 49 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.